CD8+ TCR bias and immunodominance in HIV-1 infection

  • Henrik N. Kløverpris ,
  • Reuben McGregor ,
  • James E. McLaren ,
  • Kristin Ladell ,
  • Mikkel Harndahl ,
  • Anette Stryhn ,
  • ,
  • Catherine Koofhethile ,
  • Bram Gerritsen ,
  • Can Kesmir ,
  • Fabian Chen ,
  • Lynn Riddell ,
  • Graz Luzzi ,
  • Alasdair Leslie ,
  • Bruce D. Walker ,
  • Thumbi Ndung'u ,
  • Søren Buus ,
  • David A. Price ,
  • Philip J.R. Goulder

The Journal of Immunology | , Vol 194: pp. 5329-5345

Publication | Publication

Immunodominance describes a phenomenon whereby the immune system consistently targets only a fraction of the available Ag pool derived from a given pathogen. In the case of CD8+ T cells, these constrained epitope-targeting patterns are linked to HLA class I expression and determine disease progression. Despite the biological importance of these predetermined response hierarchies, little is known about the factors that control immunodominance in vivo. In this study, we conducted an extensive analysis of CD8+ T cell responses restricted by a single HLA class I molecule to evaluate the mechanisms that contribute to epitope-targeting frequency and antiviral efficacy in HIV-1 infection. A clear immunodominance hierarchy was observed across 20 epitopes restricted by HLA-B*42:01, which is highly prevalent in populations of African origin. Moreover, in line with previous studies, Gag-specific responses and targeting breadth were associated with lower viral load set-points. However, peptide–HLA-B*42:01 binding affinity and stability were not significantly linked with targeting frequencies. Instead, immunodominance correlated with epitope-specific usage of public TCRs, defined as amino acid residue–identical TRB sequences that occur in multiple individuals. Collectively, these results provide important insights into a potential link between shared TCR recruitment, immunodominance, and antiviral efficacy in a major human infection.

Publication Downloads

PhyloD

March 25, 2016

Machine learning tools for modeling viral adaptation to host immune responses.